Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Efficacy of Multiple Subcutaneous Injections of Depot Buprenorphine (RBP 6000) Over 24 Weeks in Treatment-Seeking Participants With Opioid Use Disorder

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Efficacy of Multiple Subcutaneous Injections of Depot Buprenorphine (RBP 6000) Over 24 Weeks in Treatment-Seeking Participants With Opioid Use Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Buprenorphine (Primary) ; Buprenorphine (Primary)
  • Indications Opioid abuse
  • Focus Registrational; Therapeutic Use
  • Sponsors Indivior
  • Most Recent Events

    • 31 Jul 2017 According to an Indivior media release, U.S. Food and Drug Administration (FDA) has accepted with a Priority Review designation the New Drug Application (NDA) for RBP-6000, an investigational once-monthly injectable buprenorphine in the ATRIGEL delivery system for the treatment of adults with moderate-to-severe opioid use disorder (OUD) as part of a complete treatment plan to include counseling and psychosocial support.
    • 21 Jun 2017 Results from this trial published in an Indivior Media Release.
    • 21 Jun 2017 According to an Indivior media release data from this trial were presented at the 79th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top